Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

[1] Tariq NU(2019)Biliary tract cancers: current knowledge, clinical candidates and future challenges Cancer Manag Res 11 2623-2642

[2] McNamara MG(2016)Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations Chin Clin Oncol 5 61-1498

[3] Valle JW(2019)Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013 Cancer. 125 1489-1788

[4] Marcano-Bonilla L(2018)Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 392 1736-361

[5] Mohamed EA(2015)Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review Cancer Res Treat 47 343-485

[6] Mounajjed T(2020)Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience Int J Hyperth 27 479-1958

[7] Roberts LR(2019)Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial Ann Oncol 30 1950-425

[8] Van Dyke AL(2018)Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA) [abstract] Ann Oncol 29 Abstract 6150-883

[9] Shiels MS(2008)Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma Br J Cancer 98 418-60

[10] Jones GS(2003)Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas Eur J Surg Oncol 29 879-1802

[1] Tariq NU(2019)Biliary tract cancers: current knowledge, clinical candidates and future challenges Cancer Manag Res 11 2623-2642

[2] McNamara MG(2016)Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations Chin Clin Oncol 5 61-1498

[3] Valle JW(2019)Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013 Cancer. 125 1489-1788

[4] Marcano-Bonilla L(2018)Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 392 1736-361

[5] Mohamed EA(2015)Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review Cancer Res Treat 47 343-485

[6] Mounajjed T(2020)Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience Int J Hyperth 27 479-1958

[7] Roberts LR(2019)Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial Ann Oncol 30 1950-425

[8] Van Dyke AL(2018)Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA) [abstract] Ann Oncol 29 Abstract 6150-883

[9] Shiels MS(2008)Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma Br J Cancer 98 418-60

[10] Jones GS(2003)Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas Eur J Surg Oncol 29 879-1802